Novo Nordisk (NVO) (OTCPK:NONOF) announced on Sunday that its popular weight loss drug Wegovy resulted in more than a 50% decrease in serious heart issues such as stroke compared to Eli Lilly’s (NYSE:LLY) competing drug
Novo’s Wegovy beats Lilly’s Zepbound in real-world study for heart diseases
